Clinical Trial Update: Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Saruparib (AZD5305) versus placebo in men with metastatic castration-sensitive prostate cancer receiving physician's choice new hormona…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-sensitive Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Saruparib (saruparib)

Snippet

Sponsor: AstraZeneca | Conditions: Metastatic Castration-Sensitive Prostate Cancer | Phase 3 | Status: RECRUITING